Treatment Study for Patients with Localized Central Nervous System Germ Cell Tumors

Clinical Trial Title

Phase 2 trial of response-based radiation therapy for patients with localized central nervous system germ cell tumors (CNS GCT).

Contact Information

Nitin Sane

Clinical Trial Protocol Description:

To determine, as measured by the 3-year progression free survival rate and patterns of failure, whether simplified chemotherapy followed by dose-reduced radiation therapy is effective for treating children and young adults (ages 3 to < 21 years) with localized  primary central nervous system (CNS) germinoma who present with serum and/or CSF human chorionic gonadotropin-beta (hCGI3) < 50miU/ml.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are between 3 and 21 years of age at the time of study enrollment.
  • Have been newly diagnosed with localized primary CNS NGGCT (Stratum  1) or localized primary CNS germinoma (Stratum 2). Germ cell tumors located in the suprasellar  pineal, bifocal (pineal + suprasellar) and ventricles are eligible. Tumors present  in the above mentioned locations and with unifocal parenchymal extension are eligible.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Mary Lou Schmidt, MD

Contact Information

Nitin Sane

(312) 355-0741

Location

Rush University Cancer Center

1725 W Harrison St
Professional Building - Suite 1010
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more